COVID-19 and Venous Thromboembolism Risk

CompletedOBSERVATIONAL
Enrollment

398,530

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

February 28, 2021

Study Completion Date

June 21, 2022

Conditions
Venous ThromboembolismCovid19
Interventions
OTHER

Laboratory test positive for SARS-CoV-2 virus

Exposure/intervention: diagnosis of Covid-19, defined as positive laboratory test for SARS-CoV-2

Trial Locations (2)

91101

Kaiser Permanente Southern California, Pasadena

94612

Kaiser Permanente Northern California, Oakland

All Listed Sponsors
collaborator

Kaiser Permanente

OTHER

collaborator

Patient-Centered Outcomes Research Institute

OTHER

lead

University of California, San Francisco

OTHER

NCT04569344 - COVID-19 and Venous Thromboembolism Risk | Biotech Hunter | Biotech Hunter